– Novartis declares two deaths of children treated with Zolgensma
The Swiss pharmaceutical giant continues to “firmly believe” in this gene therapy, which cost two million dollars when it was launched in 2019.
Swiss pharmaceutical giant Novartis has warned health authorities of the deaths of two children treated with Zolgensma, a gene therapy for a rare and often fatal condition for which there were no treatment options until the drug arrived. , he said on Friday.
These two deaths occurred in Russia and Kazakhstan, said the Swiss group in an email to AFP. These children died of acute liver failure five to six weeks following receiving this treatment and one to ten days following the administration of corticosteroids which must be dispensed followingwards to reduce adverse effects, he explains.
Novartis nevertheless affirmed to continue to “firmly believe” in this treatment with regard to the risks for patients affected by this disease. Globally, Zolgensma has been used to treat over 2,300 patients since its launch.
AFP
You found an error?Please let us know.